Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 674

1.

HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease.

Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, Heeren T, Koziel M, Graham C, Craven DE, Stuver S, Horsburgh CR Jr.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):538-44.

PMID:
16284529
2.

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH.

J Hepatol. 2005 Jul;43(1):78-84.

PMID:
15894397
3.

Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.

Toniutto P, Fabris C, Bitetto D, Falleti E, Avellini C, Rossi E, Smirne C, Minisini R, Pirisi M.

J Gastroenterol Hepatol. 2007 Nov;22(11):1904-8.

PMID:
17914968
4.

Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort.

Loko MA, Castera L, Dabis F, Le Bail B, Winnock M, Coureau G, Bioulac-Sage P, de Ledinghen V, Neau D; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)..

Am J Gastroenterol. 2008 Aug;103(8):1973-80. doi: 10.1111/j.1572-0241.2008.01954.x.

PMID:
18796094
5.
6.

Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection.

Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, Sampaio JP, Lanzoni VP, Ferraz ML, Silva AE.

Liver Int. 2008 Apr;28(4):486-93. doi: 10.1111/j.1478-3231.2008.01675.x.

PMID:
18339075
7.

Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker.

Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):463-9.

PMID:
17211282
8.

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE.

Hepatology. 2005 Jun;41(6):1376-82.

PMID:
15915455
9.

Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice.

Macías J, González J, Ortega E, Tural C, Cabrero E, Burgos A, Pineda JA; GRAFIHCO Study Team..

HIV Med. 2010 Aug;11(7):439-47. doi: 10.1111/j.1468-1293.2009.00812.x.

10.

APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C.

Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J.

J Clin Gastroenterol. 2006 Jul;40(6):535-42.

PMID:
16825937
11.

Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.

Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, Moore RD, Afdhal NH, Thomas DL.

AIDS. 2007 Oct 18;21(16):2209-16.

PMID:
18090048
12.

Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers.

Islam S, Antonsson L, Westin J, Lagging M.

Scand J Gastroenterol. 2005 Jul;40(7):867-72.

PMID:
16109665
13.

A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice.

Giannini EG, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R.

J Clin Gastroenterol. 2006 Jul;40(6):521-7.

PMID:
16825935
14.

Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients.

de Lédinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, Dhumeaux D, Beaugrand M.

J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):175-9.

PMID:
16394849
15.

[Valuation of APRI and Forns models for non-invasive diagnosis of fibrosis in patients with hepatitis C in coinfected and non-coinfected with HIV].

Ramos Paesa C, Marcilla F, López G, Hueso E, Pascual A, Aguirre JM.

An Med Interna. 2007 Aug;24(8):369-74. Spanish.

PMID:
18020875
16.

Progression of liver fibrosis among injection drug users with chronic hepatitis C.

Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL.

Hepatology. 2006 Apr;43(4):788-95.

PMID:
16557548
17.

[Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease].

Kim SM, Sohn JH, Kim TY, Roh YW, Eun CS, Jeon YC, Han DS, Oh YH.

Korean J Hepatol. 2009 Dec;15(4):454-63. doi: 10.3350/kjhep.2009.15.4.454. Korean.

18.

Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.

Macías J, Girón-González JA, González-Serrano M, Merino D, Cano P, Mira JA, Arizcorreta-Yarza A, Ruíz-Morales J, Lomas-Cabeza JM, García-García JA, Corzo JE, Pineda JA.

Gut. 2006 Mar;55(3):409-14.

19.

Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: the HGM-3 index.

Resino S, Micheloud D, Miralles P, Bellón JM, Vargas A, Catalán P, Alvarez E, Cosín J, Lorente R, López JC, Muñoz-Fernández MA, Berenguer J.

HIV Med. 2010 Jan;11(1):64-73. doi: 10.1111/j.1468-1293.2009.00745.x.

20.

Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection.

Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, Koziel MJ, Graham C, Tumilty S, Skolnik P, Stuver S, Horsburgh CR Jr, Cotton D.

Am J Gastroenterol. 2010 Jun;105(6):1346-53. doi: 10.1038/ajg.2009.746.

PMID:
20179698
Items per page

Supplemental Content

Support Center